We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$283M
AUM Growth
+$191M
Cap. Flow
+$202M
Cap. Flow %
71.4%
Top 10 Hldgs %
97.95%
Holding
31
New
8
Increased
5
Reduced
7
Closed
6

Top Buys

1
LITS
Lite Strategy Inc
LITS
+$13.5M
2
AMLP icon
Alerian MLP ETF
AMLP
+$4.25M
3
ICMB icon
Investcorp Credit Management BDC
ICMB
+$683K
4
MRKR icon
Marker Therapeutics
MRKR
+$432K
5
KURA icon
Kura Oncology
KURA
+$278K

Top Sells

1
AGRX
Agile Therapeutics
AGRX
+$4.66M
2
SCYX icon
SCYNEXIS
SCYX
+$2.85M
3
FSK icon
FS KKR Capital
FSK
+$508K
4
BUD icon
AB InBev
BUD
+$486K
5
BBDC icon
Barings BDC
BBDC
+$258K

Sector Composition

1 Healthcare 22.26%
2 Financials 3.51%
3 Real Estate 0.53%
4 Industrials 0.34%
5 Utilities 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$193M 68.07%
+710,100
New +$192M
SBBP
2
DELISTED
Strongbridge Biopharma plc.
SBBP
$32.4M 11.44%
5,398,034
+21,995
+0.4% +$161K
LITS
3
Lite Strategy Inc
LITS
$33.6M
$17.3M 6.13%
+220,022
New +$13.5M
GARS
4
DELISTED
Garrison Capital Inc.
GARS
$9.09M 3.21%
1,118,529
+3,457
+0.3% +$29K
ICMB icon
5
Investcorp Credit Management BDC
ICMB
$12.3M
$7.91M 2.79%
894,438
+78,998
+10% +$683K
MTEM
6
DELISTED
Molecular Templates, Inc.
MTEM
$5.51M 1.95%
70,252
+1,000
+1% +$113K
SCYX icon
7
SCYNEXIS
SCYX
$42.4M
$4.85M 1.71%
36,938
-23,942
-39% -$2.85M
AMLP icon
8
Alerian MLP ETF
AMLP
$12.7B
$4.23M 1.5%
+83,821
New +$4.25M
BRK.B icon
9
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.74M 0.61%
9,312
– –
JBGS
10
JBG SMITH
JBGS
$867M
$1.5M 0.53%
41,170
– –
UHAL icon
11
U-Haul Holding Co
UHAL
$13.9B
$962K 0.34%
27,000
– –
PCG icon
12
PG&E
PCG
$38.1B
$958K 0.34%
22,500
– –
MRKR icon
13
Marker Therapeutics
MRKR
$21.8M
$798K 0.28%
+8,467
New +$432K
ONCT
14
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$763K 0.27%
356
+3
+0.8% +$7.61K
ACRS icon
15
Aclaris Therapeutics
ACRS
$793M
$390K 0.14%
19,514
-1,628
-8% -$30.1K
ABDC
16
DELISTED
Alcentra Capital Corp
ABDC
$354K 0.13%
55,359
-8,777
-14% -$58.5K
BBDC icon
17
Barings BDC
BBDC
$890M
$302K 0.11%
26,286
-22,545
-46% -$258K
KURA icon
18
Kura Oncology
KURA
$964M
$299K 0.11%
+16,415
New +$278K
INDP icon
19
Indaptus Therapeutics
INDP
$337M
$285K 0.1%
29
– –
FPAC.U
20
DELISTED
Far Point Acquisition Corporation Units, each consisting of one share of Class A common stock, $0.00
FPAC.U
$225K 0.08%
+22,104
New +$225K
CPRX icon
21
Catalyst Pharmaceutical
CPRX
$105K 0.04%
33,801
-2,278
-6% -$6.91K
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$103K 0.04%
+1,392
New +$124K
SRRA
23
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$100K 0.04%
843
-97
-10% -$9.73K
MRNS
24
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$93K 0.03%
3,276
-3,431
-51% -$76.1K
ARQL
25
DELISTED
Arqule Inc
ARQL
$72K 0.03%
+12,959
New +$49.5K
1
2

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q2 2018 Portfolio in Review

As of Q2 2018, Caxton Corporation held 31 positions worth $283M, up 207% from $92.1M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caxton Corporation deployed $202M of net new capital in Q2 2018, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Lite Strategy Inc: 220,022 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 70% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was SCYNEXIS, an estimated $2.85M trimmed.

  • Caxton Corporation's largest Q2 2018 buy was Lite Strategy Inc: 220,022 shares worth $17.3M.
  • Caxton Corporation added most to Investcorp Credit Management BDC in Q2 2018, an estimated $683K increase.
  • Caxton Corporation's biggest Q2 2018 reduction was SCYNEXIS, cutting an estimated $2.85M.
  • Caxton Corporation fully exited Agile Therapeutics in Q2 2018, selling an estimated $4.66M.
  • Caxton Corporation's ten largest holdings make up 98% of its $283M portfolio in Q2 2018.
  • Caxton Corporation opened 8 new positions and closed 6 in Q2 2018.
  • Caxton Corporation's portfolio value rose 207% quarter-over-quarter to $283M.

Based on Caxton Corporation's 13F filing for Q2 2018, filed 14 Aug 2018.